Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Gregory Madison has resigned as president and chief executive officer of the company and his seat on its board of directors, effective immediately. Jodie Morrison, a member of the company’s board of directors, has been named …

As quoted in the press release:

“On behalf of the entire board I would like to thank Greg for his contributions to Keryx over the past four years, in particular for his role in transitioning Keryx from a development-stage organization to a commercial entity, and wish him well in his future endeavors,” said Michael Rogers, chairman of Keryx’s board of directors. “We are fortunate to have Jodie – a fellow director – step into a management role and help lead Keryx as we continue to execute on our strategic priorities. We look forward to her continued contributions both as an ongoing member of our board and as interim CEO while we conduct the search for a permanent chief executive officer.”
“We have a very talented leadership team at Keryx and I look forward to working with them to review our business in the coming weeks,” said Jodie Morrison, interim chief executive officer of Keryx. “Auryxia is an important therapy with the potential to benefit millions of people in the U.S. living with chronic kidney disease (CKD) and iron deficiency anemia or hyperphosphatemia. The board and the entire leadership team at Keryx are focused on ensuring that we maximize the value of Auryxia and help as many patients as possible who are living with these complications of CKD.”

Click here to read the full press release.